On September 24, 2021, the board of directors of Jiya Acquisition Corp. announced that Dr. Lori Friedman, PhD was appointed to serve as a Class I director of the Company with a term expiring at the Company’s first annual meeting of stockholders. Dr. Friedman was determined to be an independent director as defined in the applicable Nasdaq listing standards, and she was appointed to the Board’s audit committee and as chair of the Board’s compensation committee. Lori Friedman is currently the Chief Scientific Officer at ORIC Pharmaceuticals where she leads discovery research, preclinical development sciences and manufacturing. Prior to ORIC, Lori spent 15 years at Genentech.